WAS
CTXR icon

Wealth Advisory Solutions’s Citius Pharmaceuticals CTXR Stock Holding History

Wealth Advisory Solutions’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,040
Closed -$101K – 129
2024
Q3 		$101K Buy
8,040
+2,000
+33% +$33.7K 0.03% 122
2024
Q2 		$88.1K Hold
6,040
– – 0.02% 123
2024
Q1 		$135K Buy
+6,040
New +$110K 0.04% 123
2023
Q4 		– Sell
-6,165
Closed -$105K – 83
2023
Q3 		$105K Buy
+6,165
New +$147K 0.02% 115
2023
Q2 		– Sell
-6,234
Closed -$182K – 100
2023
Q1 		$182K Hold
6,234
– – 0.05% 126
2022
Q4 		$123K Sell
6,234
-40
-0.6% -$1.09K 0.03% 129
2022
Q3 		$190K Hold
6,274
– – 0.05% 129
2022
Q2 		$144K Hold
6,274
– – 0.04% 143
2022
Q1 		$281K Buy
+6,274
New +$248K 0.06% 127
2021
Q3 		$318K Hold
6,274
– – 0.07% 128
2021
Q2 		$546K Buy
6,274
+2,000
+47% +$120K 0.13% 103
2021
Q1 		$0 Buy
4,274
+40
+0.9% +$1.59K ﹤0.01% 145
2020
Q4 		$107K Buy
+4,234
New +$110K 0.03% 158

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Wealth Advisory Solutions's CTXR Position: Q4 2024 in Review

Wealth Advisory Solutions sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 8,040 shares — an estimated $101K sold.

Wealth Advisory Solutions first reported a position in CTXR in Q4 2020 and held it in 13 quarters. The position peaked at $546K in Q2 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Wealth Advisory Solutions reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Wealth Advisory Solutions sold 8,040 Citius Pharmaceuticals shares in Q4 2024, an estimated $101K.
  • Wealth Advisory Solutions first reported a position in Citius Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Wealth Advisory Solutions's Citius Pharmaceuticals position peaked at $546K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Wealth Advisory Solutions's 13F filing for Q4 2024, filed 6 Feb 2025.